ATE180261T1 - Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen - Google Patents

Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen

Info

Publication number
ATE180261T1
ATE180261T1 AT91903010T AT91903010T ATE180261T1 AT E180261 T1 ATE180261 T1 AT E180261T1 AT 91903010 T AT91903010 T AT 91903010T AT 91903010 T AT91903010 T AT 91903010T AT E180261 T1 ATE180261 T1 AT E180261T1
Authority
AT
Austria
Prior art keywords
proteins
pharmaceutical
human lymphocytes
dna coding
biological uses
Prior art date
Application number
AT91903010T
Other languages
English (en)
Inventor
Thierry Hercend
Frederic Triebel
Original Assignee
Inst Nat Sante Rech Med
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Roussy Inst Gustave filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE180261T1 publication Critical patent/ATE180261T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91903010T 1990-01-08 1991-01-08 Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen ATE180261T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000126A FR2656800B1 (fr) 1990-01-08 1990-01-08 Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.

Publications (1)

Publication Number Publication Date
ATE180261T1 true ATE180261T1 (de) 1999-06-15

Family

ID=9392569

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91903010T ATE180261T1 (de) 1990-01-08 1991-01-08 Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen

Country Status (13)

Country Link
US (2) US5773578A (de)
EP (1) EP0510079B1 (de)
JP (1) JP2997053B2 (de)
AT (1) ATE180261T1 (de)
DE (1) DE69131249T2 (de)
DK (1) DK0510079T3 (de)
ES (1) ES2134770T3 (de)
FR (1) FR2656800B1 (de)
GR (1) GR3030811T3 (de)
IL (1) IL96907A (de)
MX (1) MX9203379A (de)
WO (1) WO1991010682A1 (de)
ZA (1) ZA91134B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
AU755030B2 (en) * 1994-05-06 2002-11-28 Institut Gustave Roussy LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
JP3700859B2 (ja) 1994-05-06 2005-09-28 アンスティテュ ギュスタブ ルシ Lag−3タンパク質の可溶性ポリペプチドフラクション;製造方法、治療用製剤、抗イディオタイプ抗体
DK0843557T3 (da) * 1995-07-21 2003-03-10 Inst Nat Sante Rech Med Fremgangsmåder til detektion, identifikation, isolation og selektiv mærkning og målsøgning af Th1-lymfocytter ved hjælp af LAG-3 protein
EA003772B1 (ru) * 1996-11-29 2003-08-28 Апплайд Резеч Системз Арс Холдинг Н.В. Средство для обеспечения защиты трансплантата от отторжения иммунной системой хозяина на основе штамма генетически сконструированных эукариотических клеток, содержащих днк, кодирующую трансмембранный белок lag-3
EP0900841A1 (de) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Spleissvarianten von LAG-3
EP0893507A1 (de) * 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
AU2183300A (en) * 1998-12-18 2000-07-12 Incyte Pharmaceuticals, Inc. Lymphocytic membrane proteins
SE0103423D0 (sv) * 2001-10-12 2001-10-12 Astrazeneca Ab Polymorphism
US20040258678A1 (en) * 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
FI1897548T4 (fi) 2003-02-28 2024-09-03 The Johns Hopkins University T-solujen säätely
KR100808925B1 (ko) 2006-09-29 2008-03-03 고려대학교 산학협력단 돼지 lag-3 융합 이뮤노글로블린
EP2044949A1 (de) 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
RS58705B1 (sr) 2013-09-20 2019-06-28 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CU24481B1 (es) 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
KR102504758B1 (ko) 2014-07-16 2023-02-28 트랜스진 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물
WO2016008976A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
PL3328419T3 (pl) 2015-07-30 2021-12-27 Macrogenics, Inc. Cząsteczki wiążące pd-1 i sposoby ich zastosowania
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
KR102424513B1 (ko) 2015-12-14 2022-07-25 마크로제닉스, 인크. Pd-1 및 ctla-4과의 면역반응성을 가진 이중특이적 분자, 및 이것의 사용 방법
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
CN118557758A (zh) 2017-02-10 2024-08-30 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
KR20190137911A (ko) 2017-04-21 2019-12-11 신라젠(주) 항암 백시니아 바이러스와 관문 저해제 병용 요법
MX2019012032A (es) 2017-05-30 2019-10-30 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
US20220193198A1 (en) 2019-03-29 2022-06-23 Institut Curie Interleukin-2 Variants with Modified Biological Activity
JP2022532490A (ja) 2019-05-13 2022-07-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ
US20220401539A1 (en) 2019-10-22 2022-12-22 Institut Curie Immunotherapy Targeting Tumor Neoantigenic Peptides
EP3824954A1 (de) 2019-11-22 2021-05-26 Centre National de la Recherche Scientifique Vorrichtung, einrichtung und verfahren zur ministrahl-strahlentherapie
WO2021224186A1 (en) 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
CN115968377A (zh) 2020-05-20 2023-04-14 居里研究所 单域抗体及其在癌症治疗中的用途
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
WO2022084325A1 (en) 2020-10-20 2022-04-28 Institut Curie Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
JP2023550402A (ja) 2020-11-18 2023-12-01 アンスティテュ・クリー ビグアニジンの二量体及びその治療的使用
US20240317890A1 (en) 2021-01-14 2024-09-26 Institut Curie Her2 single domain antibodies variants and cars thereof
WO2022189618A1 (en) 2021-03-12 2022-09-15 Institut Curie Nitrogen-containing heterocycles as radiosensitizers
US20240269282A1 (en) 2021-05-10 2024-08-15 Institut Curie Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
WO2023011879A1 (en) 2021-08-05 2023-02-09 Institut Curie Scanning dynamic device for minibeams production
EP4401715A1 (de) 2021-09-17 2024-07-24 Institut Curie Bet-inhibitoren zur behandlung von pab1-defizientem krebs
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
WO2023180552A1 (en) 2022-03-24 2023-09-28 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023194608A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
WO2023194607A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
WO2024068617A1 (en) 2022-09-26 2024-04-04 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
WO2024192033A1 (en) 2023-03-13 2024-09-19 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
WO2024194401A1 (en) 2023-03-21 2024-09-26 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US4994369A (en) * 1987-12-15 1991-02-19 The Board Of Trustees Of The Leland Stanford Jr. Univ. T-cell activation related gene
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers

Also Published As

Publication number Publication date
IL96907A (en) 1998-10-30
DE69131249D1 (de) 1999-06-24
JPH05503520A (ja) 1993-06-10
IL96907A0 (en) 1992-03-29
EP0510079B1 (de) 1999-05-19
ZA91134B (en) 1992-08-26
US5773578A (en) 1998-06-30
FR2656800A1 (fr) 1991-07-12
JP2997053B2 (ja) 2000-01-11
EP0510079A1 (de) 1992-10-28
GR3030811T3 (en) 1999-11-30
WO1991010682A1 (fr) 1991-07-25
DE69131249T2 (de) 1999-12-30
FR2656800B1 (fr) 1992-05-15
US5874250A (en) 1999-02-23
DK0510079T3 (da) 1999-11-29
MX9203379A (es) 1992-09-01
ES2134770T3 (es) 1999-10-16

Similar Documents

Publication Publication Date Title
ATE180261T1 (de) Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen
ES2142953T3 (es) Factor de crecimiento y diferenciacion de la familia del tgf-beta.
DE69016426D1 (de) Biologische klappenprothese.
ITTO950367A0 (it) Proteine di prrsv ricombinanti, corredi diagnostici e vaccini contenenti tali proteine di prrsv ricombinanti.
AU3310595A (en) Compositions and methods for identifying biologically active molecules
NO971875D0 (no) Cathepsin 02 protease
FR2661187B1 (fr) Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
NO891805L (no) Flertrinns biologisk renseanlegg.
DE69728897D1 (de) Saeugetierchemokine
ATE344325T1 (de) Neisseria lactoferrin-bindendes protein
ATE278781T1 (de) Tioredioxine h aus zwig und hart-weizen und ähnliche proteine, diese kodierende dna-fragmente und verfahren zu ihrer herstellung
DE68912536D1 (de) Flüssiges Nahrungsmittel zur Proteinzuführung.
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
DE59611307D1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
PT676413E (pt) Proteina de ligacao a interferoes alfa/beta, sua preparacao e utilizacao
AU4981093A (en) Nucleotide sequences coding for cryptosporidium proteins, polypeptides coded by said sequences and kits for the use thereof
FI880412A (fi) Biologisk respons modifierande aemne.
TR26931A (tr) Lak koagülasyonunda molipten bilesiklerinin kullanilmasi.
NO905496D0 (no) Biologisk forenelige, stoff-spesifikke reagenser til behandling av fysiologiske vaesker.
EP0780472A3 (de) Stress Proteine
DE3880486D1 (de) Aspirator zur aufnahme von koerperfluessigkeiten.
FI885025A (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
DE59611293D1 (de) Protein mit dnase-aktivität
RU95114858A (ru) Новый пептидный фрагмент, обладающий биологической активностью инсулина
ATE193324T1 (de) Rekombinante herstellung von laktoperoxidase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee